Promoting Inclusion of Members of Racial and Ethnic Minority Groups in Cancer Drug Development
Authors:
- 1 October 2021
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 7 (10) , 1445-1446
Abstract
This Viewpoint discusses the need to develop a framework to improve inclusion of members of racial and ethnic minority groups, who are often underrepresented inKeywords
This publication has 3 references indexed in Scilit:
- Racial composition in trials supporting the U.S. approval of anti-cancer new molecular entities (NMEs): 2011- 2016.Journal of Clinical Oncology, 2017
- Under‐representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993‐2013Cancer, 2014
- The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancerEuropean Respiratory Review, 2010